4
Orphan Designations
0 approved, 4 designated
0
FDA Approvals
0
Active Trials
8
Rare Diseases
across 13 areas
0
News (30d)
Quiet
Aldeyra Therapeutics, Inc. is a company with 4 orphan drug designations across 8 rare diseases.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| CAPN5-related vitreoretinopathy | methotrexate | Des.TrialAppr. |
| inherited ichthyosis | 2-(3-amino-6-chloroquinolin-2-yl)-propan-2-ol | Des.TrialAppr. |
| primary biliary cholangitis | methotrexate (intravitreal) | Des.TrialAppr. |
| primary cutaneous lymphoma | methotrexate (intravitreal) | Des.TrialAppr. |
| primary hyperoxaluria | methotrexate (intravitreal) | Des.TrialAppr. |
| proliferative fasciitis | methotrexate | Des.TrialAppr. |
| proliferative vitreoretinopathy | methotrexate | Des.TrialAppr. |
| retinitis pigmentosa | Methotrexate | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
12
overlap in 2+ diseases
0/8
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
12
overlap in 2+ diseases
0/8
candidate diseases
0
avg importance: 0
0
affecting portfolio